- Zacks Small Cap Research•3 months ago
DelMar initiated the Phase I/II clinical trial of VAL-083 for the treatment of refractory glioblastoma multiforme (GBM) or progressive secondary brain tumor in October 2011. The Phase I/II study is an open-label, single arm dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of VAL-083 in patients with histologically confirmed initial diagnosis of primary WHO Grade IV malignant glioma (GBM), now recurrent.
Del Mar Pharmaceuticals Inc.NasdaqCM
After hours: 7.050.00 (0.00%) as of 4:44 PM EDT
|Bid||6.78 x 1000|
|52wk Range||0.43 - 10.87|
|Day's Range||7.01 - 7.31|
|Avg Vol (3m)||41,215|
As of 4:00 PM EDT. Market closed.